Using surrogate failure time data to increase cost effectiveness in clinical trials

DOI10.1093/biomet/80.4.823zbMath0800.62706OpenAlexW1972164191MaRDI QIDQ4299462

Michael R. Kosorok, Thomas R. Fleming

Publication date: 4 July 1994

Published in: Biometrika (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1093/biomet/80.4.823

zbMATH Keywords

martingalecensored datalinear rank statisticmultiple endpointsasymptotic joint distributionfailure timessurrogate outcomeweighted log rank

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Related Items (6)

Improving efficiency in clinical trials using auxiliary information: Application of a multi‐state cure model ⋮ Robust Covariate‐Adjusted Log‐Rank Statistics and Corresponding Sample Size Formula for Recurrent Events Data ⋮ Using categorical markers as auxiliary variables in log-rank tests and hazard ratio estimation ⋮ Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials ⋮ Properties of A Nonparametric Test for Early Comparison of Treatments in Clinical Trials in the Presence of Surrogate Endpoints ⋮ Some comments on efficiency gains from auxiliary information for right-censored data

This page was built for publication: Using surrogate failure time data to increase cost effectiveness in clinical trials